Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02559505 · ClinicalTrials.gov registry record · NA

Influenza Immunity in Children

A NA study, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
134
Enrollment target

NCT02559505: Completed NA study, sponsored by University of Rochester.

NCT02559505 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 134 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02559505, a NA study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
134 participants
Enrollment target

Study Summary

This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.

Primary Outcome

% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining

Interventions

  • BIOLOGICAL Seasonal IIV 0.25 mL dose
  • OTHER Natural influenza infection
  • BIOLOGICAL Seasonal IIV 0.5 mL dose

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2015-10
Est. Completion 2020-07-03
Phase NA
University of Rochester

636 total trials

What the finished NCT02559505 record still lists

NCT02559505 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 3 interventions - of which Seasonal IIV 0.25 mL dose is the first listed.

NCT02559505 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02559505 about?

NCT02559505 is a clinical study titled "Influenza Immunity in Children". This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.

What is the current status of trial NCT02559505?

This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2015-10. Estimated completion is 2020-07-03.

What interventions are being tested in trial NCT02559505?

The interventions under investigation include: Seasonal IIV 0.25 mL dose (BIOLOGICAL), Natural influenza infection (OTHER), Seasonal IIV 0.5 mL dose (BIOLOGICAL).

Who is sponsoring clinical trial NCT02559505?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02559505's enrollment target sits among peer trials

134 728th of 2000 higher than 1,272 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02469662 · 134 participants · NA

    Clinical Outcomes Study of the Nexel Total Elbow

  • NCT03110822 · 134 participants · Phase 1

    A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

  • NCT04678648 · 134 participants · Phase 1

    A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  • NCT05264857 · 134 participants · NA

    Decision Aid and Thyroid Nodules Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02559505, the US trial registry maintained by the National Library of Medicine. NCT02559505 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.